OverviewChartNewsTraderScreen

UniCredit Call 29 BAYN 15.05.2024/  DE000HD4VWT9  /

Frankfurt Zert./HVB
2024-05-09  7:34:48 PM Chg.+0.005 Bid9:47:29 PM Ask9:47:29 PM Underlying Strike price Expiration date Option type
0.038EUR +15.15% 0.040
Bid Size: 150,000		 0.045
Ask Size: 150,000		 BAYER AG NA O.N. 29.00 - 2024-05-15 Call
GlobeNewswire 2:30 PM CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
GlobeNewswire 1:30 PM XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
GlobeNewswire 05-08 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire 05-02 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire 04-18 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire 04-16 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire 04-11 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire 04-09 AskBio Names Mansuo Shannon Chief Scientific Officer
GlobeNewswire 03-25 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire 03-14 Bayer and Aignostics to collaborate on next generation precision oncology
GlobeNewswire 03-06 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
TeleTrader 03-05 Bayer's Q4 sales at €11.9 billion
GlobeNewswire 03-04 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
TeleTrader 03-04 Earnings preview: Bayer, Broadcom among those in calendar
GlobeNewswire 02-15 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire 02-13 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire 02-13 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
TeleTrader 01-29 Bayer down over 5% after latest $2.25B Roundup ruling
TeleTrader 01-17 Bayer to cut jobs amid 'difficult situation'
GlobeNewswire 01-05 AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)
GlobeNewswire 01-04 AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary end...
GlobeNewswire 2023-12-14 Iktos and Bayer Announce Collaboration to expand the use of Artificial Intelligence to Design New Su...
GlobeNewswire 2023-12-06 NFWF Announces $4.1 Million in Grants to Conserve the Monarch Butterfly and Other Insect Pollinators
TeleTrader 2023-11-20 Bayer's stock slumps over 16% on study halt, Roundup ruling
GlobeNewswire 2023-11-09 Bayer and Recursion Focus Research Collaboration on Oncology